一、主要会计数据和财务指标 二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 6261.18万股，累计占流通股比： 23.81%，较上期变化： -264.70万股。 | 名称 | 持有数量(万股) | 占总股本 | 增减情况 | | --- | --- | --- | --- | | | | 比例(%) | (万股) | | 黄伟汕 | 970.18 | 3.69 | 不变 | | 刘文华 | 884.23 | 3.36 | -177.24 | | 深圳市聚兰德股权投资基金合伙企业(有限合伙) | 650.01 | 2.47 | 不变 | | 国泰君安证券资管-国泰君安私客尊享FOF1571号单一资产管理 | | | | | 计划-国君资管君得3481单一资产管理计划 | 643.57 | 2.45 | 不变 | | 张华明 | 628.50 | 2.39 | 不变 | | 陕西省国际信托股份有限公司-陕国投·泰恩康（301263）2024 年员工持股集合资金信托计划 | 569.43 | 2.17 | 不变 | | 张朝益 | 523.80 | 1.99 | -10.50 | | 杨时青 | 4 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-027 广东泰恩康医药股份有限公司 关于提请股东大会授权董事会办理以简易程序向 特定对象发行股票的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"或"泰恩康"）于 2025 年 4 月 24 日召开第五届董事会第七次会议，审议通过了《关于提请股东大会授权 董事会办理以简易程序向特定对象发行股票的议案》。根据《上市公司证券发行 注册管理办法》《深圳证券交易所上市公司证券发行上市审核规则》《深圳证券 交易所上市公司证券发行与承销业务实施细则》等相关规定，公司董事会提请股 东大会授权董事会办理以简易程序向特定对象发行融资总额不超过人民币 3 亿 元且不超过最近一年末净资产 20%的股票，授权期限为公司 2024 年年度股东大 会通过之日起至 2025 年年度股东大会召开之日止。上述事项尚需提交公司 2024 年年度股东大会审议。现将有关情况公告如下： 本次以简易程序向特定对象发行的股票种类为境内上市的人民币普通股（A 股），每股面值为人民币 1.00 元。本 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥184,664,794.23, a decrease of 2.35% compared to ¥189,109,474.07 in the same period last year[5] - Net profit attributable to shareholders for Q1 2025 was ¥31,545,960.13, down 30.62% from ¥45,467,802.98 year-on-year[5] - Basic and diluted earnings per share decreased by 36.36%, from ¥0.11 to ¥0.07[5] - Total operating revenue for the current period is ¥184,664,794.23, a decrease of 2.3% from ¥189,109,474.07 in the previous period[19] - Net profit for the current period is ¥30,693,844.13, down 27.7% from ¥42,427,049.27 in the previous period[21] - Operating profit decreased to ¥38,880,530.27, a decline of 29.5% from ¥55,234,552.85 in the previous period[20] - Basic earnings per share for the current period is ¥0.07, compared to ¥0.11 in the previous period[21] Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥39,068,525.84, worsening by 17.53% compared to the previous year's negative cash flow of ¥33,240,384.68[5] - Cash received from operating activities totaled 126,063,087.23, slightly down from 136,954,879.04, suggesting a decline in operational efficiency[24] - Cash inflow from investment activities totaled 90,373,851.79, up from 46,531,726.19, reflecting an increase in investment recovery[24] - Net cash flow from investment activities was -93,731,124.62, compared to -32,973,274.36 previously, showing a significant increase in cash outflows for investments[25] - Cash inflow from financing activities reached 203,969,120.00, significantly higher than 61,000,000.00 in the prior period, indicating strong borrowing activity[25] - Net cash flow from financing activities was 75,219,879.39, compared to 33,498,725.43, reflecting improved financing conditions[25] - The ending balance of cash and cash equivalents was 482,530,725.52, down from 540,108,625.66, indicating a decrease in liquidity[25] Assets and Liabilities - Total assets increased by 3.71% to ¥2,396,801,627.33 from ¥2,311,053,816.34 at the end of the previous year[5] - Total liabilities rose to ¥549,920,247.46, an increase from ¥494,668,321.40 in the previous period[17] - Non-current liabilities decreased to ¥106,776,688.27 from ¥119,714,750.18 in the previous period[17] - The company's cash and cash equivalents decreased from CNY 541,958,625.66 to CNY 485,130,725.52, reflecting a decline of approximately 10.4%[15] - Accounts receivable increased from CNY 330,388,228.30 to CNY 374,357,696.54, representing a growth of about 13.3%[15] - Inventory rose from CNY 105,071,659.20 to CNY 127,158,650.56, indicating an increase of approximately 21%[15] - The total current assets increased from CNY 1,142,191,093.59 to CNY 1,223,212,923.37, showing a growth of about 7.1%[15] - The company’s fixed assets decreased from CNY 512,192,365.49 to CNY 501,760,245.02, a decline of approximately 2.5%[15] Shareholder Information - The company reported a total of 9,871 common shareholders at the end of the reporting period[11] - Major shareholder Zheng Hanjie holds 20.77% of the shares, with 66,283,515 shares pledged[11] - The total number of unrestricted shares held by the top 10 shareholders amounts to 66,283,515 shares for Zheng Hanjie and 49,662,652 shares for Sun Weiwen, both of whom are in a spousal relationship[12] - The total number of restricted shares held by Zheng Hanjie decreased by 22,094,505 shares, while Sun Weiwen's restricted shares decreased by 16,554,218 shares[13] - The company has a total of 121,911,445 shares remaining under restriction after the recent unlocks[13] - The total number of shares held by the top 10 unrestricted shareholders includes significant holdings from institutional investors, such as 6,500,064 shares held by Shenzhen Juland Equity Investment Fund[12] Operating Costs and Expenses - Total operating costs increased to ¥145,905,072.17, up 6.5% from ¥136,778,024.33 in the previous period[20] - The company reported a decrease in research and development expenses to ¥14,908,408.86 from ¥16,746,979.14 in the previous period[20] - Cash paid for employee compensation was 36,083,900.37, up from 30,835,076.38, indicating rising labor costs[24] - Cash paid for taxes was 22,824,894.70, down from 29,270,585.14, reflecting a decrease in tax liabilities[24] - The company recorded a total of ¥88,501.98 in non-recurring gains and losses for the reporting period[7]

Financial Performance - The company's operating revenue for 2024 was ¥721,031,435.69, a decrease of 5.23% compared to ¥760,787,063.04 in 2023[18]. - Net profit attributable to shareholders decreased by 32.45% to ¥108,220,025.76 in 2024 from ¥160,200,147.40 in 2023[18]. - The basic earnings per share fell by 31.58% to ¥0.26 in 2024, down from ¥0.38 in 2023[18]. - The total assets increased by 3.68% to ¥2,311,053,816.34 at the end of 2024, compared to ¥2,229,112,184.59 at the end of 2023[18]. - The company reported a net cash flow from operating activities of ¥89,332,694.83, a decline of 4.48% from ¥93,525,613.07 in 2023[18]. - In Q4 2024, the company experienced a net profit loss of ¥8,115,514.81, contrasting with profits in the previous three quarters[20]. - The sales revenue of gastrointestinal drugs reached 206 million CNY, an increase of 1.04% year-on-year, while the sales revenue of sexual health drugs decreased by 20.87% to 178 million CNY[64]. - The total revenue from the pharmaceutical agency reached ¥440,515,432.12, with a year-on-year increase of 2.38%[70]. - Revenue from gastrointestinal drugs was ¥206,272,180.38, showing a growth of 1.04% compared to the previous year[70]. - The company's revenue from medical technology services and technology transfer increased by 128.22% to ¥10,866,218.20[69]. Dividend Distribution - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on a total of 423,512,382 shares[4]. - The company plans to distribute a cash dividend of 3.0 RMB per 10 shares, totaling 127,053,714.60 RMB (including tax) based on a total share capital of 423,512,382 shares[171]. - The company has not made any adjustments to its cash dividend policy during the reporting period, ensuring stability and clarity in its distribution plan[172]. - The company’s cash dividend distribution plan aligns with its articles of association and shareholder resolutions, ensuring compliance and transparency[172]. - As of December 31, 2024, the company's cumulative undistributed profit is 387,324,555.25 CNY, with 280,331,491.82 CNY available for distribution to shareholders[173]. Research and Development - The company is focused on expanding its market presence and enhancing its product offerings through ongoing R&D efforts[4]. - The company invested 158 million CNY in R&D in 2024, with significant progress in self-developed drugs, including the completion of 100% subject enrollment for the Phase II clinical trial of CKBA ointment for vitiligo[65]. - The company has established three major pharmaceutical R&D technology platforms, focusing on innovative drug research as a strategic priority[56]. - The company is actively increasing R&D investments to enrich its product pipeline in the aforementioned therapeutic areas[39]. - R&D expenses rose by 37.42% to $86.42 million in 2024 from $62.89 million in 2023, indicating a significant increase in investment in innovation[77]. - The company is focusing on innovative drug development, particularly in the field of chronic skin diseases, with CKBA ointment being a key product under development[63]. - The company is expanding its product line with new drugs targeting conditions such as asthma, Parkinson's disease, and hypertension, with several products awaiting approval in 2024 and 2025[80]. - The company has a diverse pipeline of products in various stages of development, with a strong emphasis on addressing chronic diseases and pediatric needs[80]. Market Position and Strategy - The company aims to leverage its first-mover advantage in the PE and ED drug markets to drive steady revenue growth[35]. - The company is positioned within a transforming pharmaceutical industry, focusing on structural adjustments and innovation to adapt to new market dynamics[28]. - The company aims to expand its market presence in the gastrointestinal, ophthalmic, and sexual health sectors, targeting significant sales growth in the next 3-5 years[66]. - The company plans to expand its market presence in the gastrointestinal medication sector by promoting "Hewei Zhengchang Wan" in 2-3 new regions in China by 2025[114]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $10 million earmarked for potential targets[152]. Governance and Compliance - The company has implemented a comprehensive governance structure, ensuring accountability and transparency in its operations[4]. - The company has established a performance evaluation and incentive mechanism linked to company performance and individual performance to motivate relevant personnel and maintain stability among senior management and core employees[133]. - The company has a complete and independent business system, with no reliance on or delegation to shareholders or related parties for product sales or raw material procurement during the reporting period[137]. - The company has established a value management system and disclosed a valuation enhancement plan[125]. - The company has maintained a stable governance structure, with no significant changes in the roles of the remaining directors and supervisors[144]. Environmental Compliance - The company strictly adheres to multiple environmental protection laws and standards, including the Environmental Protection Law of the People's Republic of China[186]. - The company has implemented a comprehensive waste gas treatment system, achieving a reduction in VOCs concentration from approximately 4500 mg/L to about 30 mg/L after treatment[189]. - The company has established a robust framework for managing environmental compliance, ensuring adherence to industry standards[186]. - The wastewater treatment process can handle a daily discharge of approximately 80 m³, with peak COD levels reaching 45000 mg/L, reduced to 20-160 mg/L post-treatment[191]. - The company has successfully completed the construction of its environmental protection facilities, which are currently in the debugging phase with good operational performance[189]. Employee Management - The total number of employees at the end of the reporting period is 1,081, with 339 in the parent company and 742 in major subsidiaries[166]. - The company has established a comprehensive salary management system and implements a performance evaluation system to enhance employee satisfaction and align with corporate goals[168]. - The company emphasizes talent development through a structured training program, including new employee training and management enhancement training[169]. - The company has 45 employees with master's degrees or higher, 356 with bachelor's degrees, and 324 with associate degrees[167]. - The company has a total of 1,081 employees receiving salaries, indicating a stable workforce[166]. Risks and Challenges - The company acknowledges potential risks including R&D risks, drug market entry risks, and registration expiration risks for imported drugs[4]. - The company faces risks in drug development if the products do not meet changing market demands or if similar competitive products are launched, which could impact the realization of R&D results[120].

证券代码：301263 证券简称：泰恩康 公告编号：2025-013 广东泰恩康医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 规格：10g：3g 申请人：山东华铂凯盛生物科技有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）全资子公司山东华铂 凯盛生物科技有限公司于近日收到国家药品监督管理局（以下简称"国家药监 局"）签发的蒙脱石混悬液境内生产药品注册上市许可申请《受理通知书》， 国家药监局根据《中华人民共和国行政许可法》第三十二条的规定，对上述药 品的药品注册上市许可申请进行了审查，决定予以受理。现将相关情况公告如 下： 一、申请注册药品的基本情况 受理号：CYHS2501498 药品名称：蒙脱石混悬液 申请事项：境内生产药品注册上市许可 许可药品注册分类：化学药品 4 类 五、备查文件 审核结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审 查，决定予以受理。 二、药品相关情况简介 蒙脱石混悬液是一种止泻类药品，主要用于治疗成人及儿童急、慢性腹泻， 蒙脱石在临床应用中较为成熟的产 ...

广东泰恩康医药股份有限公司 关于控股股东、实际控制人部分股份质押的公告 证券代码：301263 证券简称：泰恩康 公告编号：2025-012 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）于近日收到公司控股股 东、实际控制人郑汉杰先生、孙伟文女士的通知，获悉其所持有的公司部分股份 办理了质押手续，具体情况如下： | | 是否为 控股股 | | 占其所 | 占公司 | 是否为 限售股 | 是否 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 东或第 一大股 | 本次质押 数量 | 持股份 | 总股本 | （如 | 为补 | 质押 | 质押到 | 质权人 | 质押 | | 名称 | | | 比例 | 比例 | 是，注 | 充质 | 起始日 | 期日 | | 用途 | | | 东及其 一致行 | （股） | （%） | （%） | 明限售 | 押 | | | | | | | 动人 | | | | 类 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-010 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 广东泰恩康医药股份有限公司（以下简称"公司"）子公司山东华铂凯盛 生物科技有限公司于近日收到国家药品监督管理局（以下简称"国家药监局"） 签发的聚多卡醇注射液境内生产药品注册上市许可申请《受理通知书》，国家 药监局根据《中华人民共和国行政许可法》第三十二条的规定，对上述药品的 药品注册上市许可申请进行了审查，决定予以受理。现将相关情况公告如下： 一、申请注册药品的基本情况 广东泰恩康医药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 受理号：CYHS2501436 药品名称：聚多卡醇注射液 申请事项：境内生产药品注册上市许可 具有微创、恢复快的优势，未来市场潜力显著。 许可药品注册分类：化学药品 4 类 规格：2ml：20mg 申请人：山东华铂凯盛生物科技有限公司 审核结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审 查，决定予以受理。 二、药品相关情况简介 聚多卡醇又名聚桂醇，聚多卡醇是一种非离子型表面活性剂，通过破坏血 ...

证券代码：301263 证券简称：泰恩康 公告编号：2025-011 广东泰恩康医药股份有限公司 关于全资孙公司增资扩股引入外部投资者的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、交易概述 根据广东泰恩康医药股份有限公司（以下简称"公司"）的战略规划和经营 发展需要，为了加快推进生物制药业务板块的研发进程，公司全资孙公司安徽泰 恩康生物工程有限公司（以下简称"泰恩康生物"）通过增资扩股的方式引入外 部投资者广州赛富生物医药投资合伙企业（有限合伙）（以下简称"赛富生物"） 及宁波海厚泰仁创业投资合伙企业（有限合伙）（以下简称"海厚泰仁"），赛 富生物及海厚泰仁分别以人民币 2,750.0000 万元的价格认购泰恩康生物新增注 册资本人民币 950.2488 万元，增资价款中超出注册资本的部分计入资本公积。 泰恩康生物股东安徽泰恩康制药有限公司（以下简称"安徽泰恩康"，系公司全 资子公司）同意接受本次增资，并相应放弃对本次增资所享有的优先认购权。 本次增资完成后，泰恩康生物注册资本将由 2,000.00 万元增加至 3,980.0996 万元，公司 ...

核心观点 盈利预测与投资建议 ⚫ 公司核心业务或重要产品未来 1-2 年处于快速进展时期，我们预测公司 2024-2026 年每股收益分别为 0.26、0.39 和 0.62 元。根据可比公司 2025 年平均估值，给予公 司当年 54 倍市盈率，对应目标价 21.06 元，首次给予"增持"评级。 风险提示 研发进展不及预期风险；新产品放量低预期风险；市场竞争加剧风险；毛利率提升不及 预期风险。 泰恩康 301263.SZ 公司研究 | 首次报告 拐点将至，CKBA 打开成长空间 ——泰恩康首次覆盖报告 公司主要财务信息 | | 2022A | 2023A | 2024E | 2025E | 2026E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 783 | 761 | 757 | 951 | 1,214 | | 同比增长 (%) | 19.9% | -2.9% | -0.5% | 25.7% | 27.6% | | 营业利润(百万元) | 209 | 191 | 147 | 216 | 340 | | 同比增长 (%) | 51.0% | -8 ...

Investment Rating - The report gives the company an "Accumulate" rating for the first time, with a target price of 21.06 CNY based on a 54 times P/E ratio for 2025 [3][6]. Core Views - The company is expected to experience rapid progress in its core business or important products over the next 1-2 years, with projected earnings per share of 0.26, 0.39, and 0.62 CNY for 2024-2026 [3]. - The company has a solid foundation as a comprehensive pharmaceutical enterprise, having established a research and development platform and acquired a pipeline of high-potential products [10][15]. - The treatment for vitiligo is scarce, and the company's CKBA product is expected to stand out in the market due to its unique mechanism and promising clinical trial results [10][50]. Financial Information - The company's revenue for 2022 was 783 million CNY, with a projected revenue of 757 million CNY for 2024, followed by 951 million CNY in 2025 and 1,214 million CNY in 2026, reflecting a growth rate of 25.7% and 27.6% respectively [5]. - The net profit attributable to the parent company for 2022 was 175 million CNY, with projections of 111 million CNY for 2024, 165 million CNY for 2025, and 262 million CNY for 2026, indicating a significant growth trajectory [5]. - The gross margin is expected to improve from 58.6% in 2024 to 69.7% in 2026, while the net margin is projected to increase from 14.7% in 2024 to 21.6% in 2026 [5]. Business Overview - The company started as an agent and has developed into a comprehensive pharmaceutical enterprise, focusing on gastrointestinal, sexual health, and ophthalmic medications [10][15]. - The core products include "Hewei Zhengchang Wan" and "Woli Ting," with a strong emphasis on research and development to enhance product offerings [10][15]. - The company has significantly increased its R&D investment, leading to the successful development of key products like Dapoxetine and a rich pipeline of innovative drugs [32][34].